A high bioavailability and sustained-release nano-delivery system for nintedanib based on electrospray technology

Hongfei Liu,1,2 Kunyu Du,1 Dongli Li,2 Yi Du,2 Jumei Xi,3 Ying Xu,1 Yan Shen,4 Tao Jiang,5 Thomas J Webster6 1School of Pharmacy, Jiangsu University, Zhenjiang 212013, China; 2School of Biotechnology and Health Sciences, Wuyi University, Jiangmen 529020, China; 3Health of Nepstar Drugstore Chain Co...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Liu H, Du K, Li D, Du Y, Xi J, Xu Y, Shen Y, Jiang T, Webster TJ
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	nintedanib electrospray technology solid dispersion sustained release capsule Pharmacokinetics Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/7a026c899abf4682b8798005fee51356
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:7a026c899abf4682b8798005fee51356
record_format	dspace
spelling	oai:doaj.org-article:7a026c899abf4682b8798005fee513562021-12-02T02:56:01ZA high bioavailability and sustained-release nano-delivery system for nintedanib based on electrospray technology1178-2013https://doaj.org/article/7a026c899abf4682b8798005fee513562018-12-01T00:00:00Zhttps://www.dovepress.com/a-high-bioavailability-and-sustained-release-nano-delivery-system-for--peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Hongfei Liu,1,2 Kunyu Du,1 Dongli Li,2 Yi Du,2 Jumei Xi,3 Ying Xu,1 Yan Shen,4 Tao Jiang,5 Thomas J Webster6 1School of Pharmacy, Jiangsu University, Zhenjiang 212013, China; 2School of Biotechnology and Health Sciences, Wuyi University, Jiangmen 529020, China; 3Health of Nepstar Drugstore Chain Company Limited, Wuxi 214000, China; 4State Key Laboratory of Natural Medicines, Department of Pharmaceutics, China Pharmaceutical University, Nanjing 210009, China; 5The Pharmacy Department, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research and The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing 210009, China; 6Department of Chemical Engineering, Northeastern University, Boston, MA 02115, USA Background: Nintedanib is a new tyrosine kinase inhibitor and growth factor antagonist. It can be used to treat idiopathic pulmonary fibrosis diseases. Nintedanib has poor solubility in the intestinal tract environment, which leads to low bioavailability of just 4.7%. Methods: In this study, a nintedanib solid dispersion was prepared by electrospray technology with an optimized formula (nintedanib:PVPK30:Soybean lecithin=1:5:0.25) and electrospray parameters (21 kV voltage, 18 cm receiving distance, 0.3 mL/h solution flow rate, 0.5 mm pinhole inner diameter). Results: The accumulative release rate of the optimized solid dispersion was more than 60% in 30 minutes and 100% in 60 minutes. The size distribution was uniform and the surface observed with scanning electron microscopy (SEM) was smooth. The DSC and X-ray diffraction results showed that nintedanib existed in the solid dispersion through an amorphous form. Nintedanib solid dispersion sustained-release capsules were prepared to prolong drug release, improve patient compliance and reduce side effects. The accumulative release rate from the sustained release capsules was 35.17%, 54.78%, 70.58%, and 93.93% after 2 h, 6 h, 8 h, and 12 h, respectively, having obvious sustained release effects in vitro. The release behavior of solid dispersion sustained-release capsules in vitro was in accordance with the Ritger-Peppas model. The in vivo studies of nintedanib soft capsules, solid dispersion and nintedanib sustained release capsules in SD rats were investigated; the results showed that the Tmax of the soft capsule, solid dispersion and sustained release capsules were 3 h, 2 h, and 6 h, respectively. The Cmax were 2.945 mg/mL, 5.32 mg/mL, and 3.75 mg/mL, respectively, while the AUC0–24 h was 15.124 mg·h/mL, 23.438 mg·h/mL, and 24.584 mg·h/mL, respectively. The relevant bioavailability of the sustained-release capsules was 162.55% compared to the nintedanib soft capsule and 104.89% compared to the nintedanib solid dispersion.Conclusion: The results suggested superior bioavailability and a sustained-release effect from nintedanib sustained-release capsules, as compared to the reference (commercial nintedanib soft capsule). Keywords: nintedanib, electrospray technology, solid dispersion, sustained release capsule, pharmacokinetics Liu HDu KLi DDu YXi JXu YShen YJiang TWebster TJDove Medical Pressarticlenintedanibelectrospray technologysolid dispersionsustained release capsulePharmacokineticsMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 13, Pp 8379-8393 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	nintedanib electrospray technology solid dispersion sustained release capsule Pharmacokinetics Medicine (General) R5-920
spellingShingle	nintedanib electrospray technology solid dispersion sustained release capsule Pharmacokinetics Medicine (General) R5-920 Liu H Du K Li D Du Y Xi J Xu Y Shen Y Jiang T Webster TJ A high bioavailability and sustained-release nano-delivery system for nintedanib based on electrospray technology
description	Hongfei Liu,1,2 Kunyu Du,1 Dongli Li,2 Yi Du,2 Jumei Xi,3 Ying Xu,1 Yan Shen,4 Tao Jiang,5 Thomas J Webster6 1School of Pharmacy, Jiangsu University, Zhenjiang 212013, China; 2School of Biotechnology and Health Sciences, Wuyi University, Jiangmen 529020, China; 3Health of Nepstar Drugstore Chain Company Limited, Wuxi 214000, China; 4State Key Laboratory of Natural Medicines, Department of Pharmaceutics, China Pharmaceutical University, Nanjing 210009, China; 5The Pharmacy Department, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research and The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing 210009, China; 6Department of Chemical Engineering, Northeastern University, Boston, MA 02115, USA Background: Nintedanib is a new tyrosine kinase inhibitor and growth factor antagonist. It can be used to treat idiopathic pulmonary fibrosis diseases. Nintedanib has poor solubility in the intestinal tract environment, which leads to low bioavailability of just 4.7%. Methods: In this study, a nintedanib solid dispersion was prepared by electrospray technology with an optimized formula (nintedanib:PVPK30:Soybean lecithin=1:5:0.25) and electrospray parameters (21 kV voltage, 18 cm receiving distance, 0.3 mL/h solution flow rate, 0.5 mm pinhole inner diameter). Results: The accumulative release rate of the optimized solid dispersion was more than 60% in 30 minutes and 100% in 60 minutes. The size distribution was uniform and the surface observed with scanning electron microscopy (SEM) was smooth. The DSC and X-ray diffraction results showed that nintedanib existed in the solid dispersion through an amorphous form. Nintedanib solid dispersion sustained-release capsules were prepared to prolong drug release, improve patient compliance and reduce side effects. The accumulative release rate from the sustained release capsules was 35.17%, 54.78%, 70.58%, and 93.93% after 2 h, 6 h, 8 h, and 12 h, respectively, having obvious sustained release effects in vitro. The release behavior of solid dispersion sustained-release capsules in vitro was in accordance with the Ritger-Peppas model. The in vivo studies of nintedanib soft capsules, solid dispersion and nintedanib sustained release capsules in SD rats were investigated; the results showed that the Tmax of the soft capsule, solid dispersion and sustained release capsules were 3 h, 2 h, and 6 h, respectively. The Cmax were 2.945 mg/mL, 5.32 mg/mL, and 3.75 mg/mL, respectively, while the AUC0–24 h was 15.124 mg·h/mL, 23.438 mg·h/mL, and 24.584 mg·h/mL, respectively. The relevant bioavailability of the sustained-release capsules was 162.55% compared to the nintedanib soft capsule and 104.89% compared to the nintedanib solid dispersion.Conclusion: The results suggested superior bioavailability and a sustained-release effect from nintedanib sustained-release capsules, as compared to the reference (commercial nintedanib soft capsule). Keywords: nintedanib, electrospray technology, solid dispersion, sustained release capsule, pharmacokinetics
format	article
author	Liu H Du K Li D Du Y Xi J Xu Y Shen Y Jiang T Webster TJ
author_facet	Liu H Du K Li D Du Y Xi J Xu Y Shen Y Jiang T Webster TJ
author_sort	Liu H
title	A high bioavailability and sustained-release nano-delivery system for nintedanib based on electrospray technology
title_short	A high bioavailability and sustained-release nano-delivery system for nintedanib based on electrospray technology
title_full	A high bioavailability and sustained-release nano-delivery system for nintedanib based on electrospray technology
title_fullStr	A high bioavailability and sustained-release nano-delivery system for nintedanib based on electrospray technology
title_full_unstemmed	A high bioavailability and sustained-release nano-delivery system for nintedanib based on electrospray technology
title_sort	high bioavailability and sustained-release nano-delivery system for nintedanib based on electrospray technology
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/7a026c899abf4682b8798005fee51356
work_keys_str_mv	AT liuh ahighbioavailabilityandsustainedreleasenanodeliverysystemfornintedanibbasedonelectrospraytechnology AT duk ahighbioavailabilityandsustainedreleasenanodeliverysystemfornintedanibbasedonelectrospraytechnology AT lid ahighbioavailabilityandsustainedreleasenanodeliverysystemfornintedanibbasedonelectrospraytechnology AT duy ahighbioavailabilityandsustainedreleasenanodeliverysystemfornintedanibbasedonelectrospraytechnology AT xij ahighbioavailabilityandsustainedreleasenanodeliverysystemfornintedanibbasedonelectrospraytechnology AT xuy ahighbioavailabilityandsustainedreleasenanodeliverysystemfornintedanibbasedonelectrospraytechnology AT sheny ahighbioavailabilityandsustainedreleasenanodeliverysystemfornintedanibbasedonelectrospraytechnology AT jiangt ahighbioavailabilityandsustainedreleasenanodeliverysystemfornintedanibbasedonelectrospraytechnology AT webstertj ahighbioavailabilityandsustainedreleasenanodeliverysystemfornintedanibbasedonelectrospraytechnology AT liuh highbioavailabilityandsustainedreleasenanodeliverysystemfornintedanibbasedonelectrospraytechnology AT duk highbioavailabilityandsustainedreleasenanodeliverysystemfornintedanibbasedonelectrospraytechnology AT lid highbioavailabilityandsustainedreleasenanodeliverysystemfornintedanibbasedonelectrospraytechnology AT duy highbioavailabilityandsustainedreleasenanodeliverysystemfornintedanibbasedonelectrospraytechnology AT xij highbioavailabilityandsustainedreleasenanodeliverysystemfornintedanibbasedonelectrospraytechnology AT xuy highbioavailabilityandsustainedreleasenanodeliverysystemfornintedanibbasedonelectrospraytechnology AT sheny highbioavailabilityandsustainedreleasenanodeliverysystemfornintedanibbasedonelectrospraytechnology AT jiangt highbioavailabilityandsustainedreleasenanodeliverysystemfornintedanibbasedonelectrospraytechnology AT webstertj highbioavailabilityandsustainedreleasenanodeliverysystemfornintedanibbasedonelectrospraytechnology
_version_	1718402049458044928

A high bioavailability and sustained-release nano-delivery system for nintedanib based on electrospray technology

Ejemplares similares